HJ Burstein

481 total citations
25 papers, 223 citations indexed

About

HJ Burstein is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, HJ Burstein has authored 25 papers receiving a total of 223 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in HJ Burstein's work include Cancer Treatment and Pharmacology (15 papers), Breast Cancer Treatment Studies (13 papers) and Advanced Breast Cancer Therapies (11 papers). HJ Burstein is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), Breast Cancer Treatment Studies (13 papers) and Advanced Breast Cancer Therapies (11 papers). HJ Burstein collaborates with scholars based in United States, Belgium and Switzerland. HJ Burstein's co-authors include M. Pegram, Melody Cobleigh, Eric P. Winer, Kathy D. Miller, Charles M. Baum, Anthony Elias, Mary Collier, Hope S. Rugo, Peter D. Eisenberg and Charles Zacharchuk and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

HJ Burstein

25 papers receiving 218 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
HJ Burstein United States	8	188	84	61	51	50	25	223
Brooke Daniel United States	7	170 0.9×	58 0.7×	69 1.1×	31 0.6×	33 0.7×	17	196
Rinat Yerushalmi Israel	7	139 0.7×	47 0.6×	67 1.1×	50 1.0×	31 0.6×	11	182
Jean‐Christophe Théry France	6	129 0.7×	94 1.1×	69 1.1×	48 0.9×	31 0.6×	10	184
I. Figueiredo United Kingdom	4	88 0.5×	117 1.4×	123 2.0×	91 1.8×	18 0.4×	8	228
Tetsuhiro Yoshinami Japan	6	116 0.6×	50 0.6×	53 0.9×	33 0.6×	18 0.4×	48	174
Arielle J. Medford United States	8	139 0.7×	98 1.2×	88 1.4×	50 1.0×	38 0.8×	44	247
CE Geyer United States	9	217 1.2×	148 1.8×	71 1.2×	28 0.5×	74 1.5×	23	262
Ignacio Tusquets Spain	9	131 0.7×	59 0.7×	110 1.8×	50 1.0×	21 0.4×	16	252
Yizhao Xie China	9	100 0.5×	71 0.8×	67 1.1×	46 0.9×	68 1.4×	31	221
Stefania Pipitone Italy	7	101 0.5×	48 0.6×	62 1.0×	56 1.1×	15 0.3×	22	175

Countries citing papers authored by HJ Burstein

Since Specialization

Citations

This map shows the geographic impact of HJ Burstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by HJ Burstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites HJ Burstein more than expected).

Fields of papers citing papers by HJ Burstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by HJ Burstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by HJ Burstein. The network helps show where HJ Burstein may publish in the future.

Co-authorship network of co-authors of HJ Burstein

This figure shows the co-authorship network connecting the top 25 collaborators of HJ Burstein. A scholar is included among the top collaborators of HJ Burstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with HJ Burstein. HJ Burstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Láng, István, Eva Ciruelos, Meritxell Bellet, et al.. (2018). Abstract GS4-03: Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial. Cancer Research. 78(4_Supplement). GS4–3. 2 indexed citations

Ligibel, JA, HS Rugo, HJ Burstein, et al.. (2018). Abstract P1-07-04: Physical activity, weight and outcomes in patients receiving first-line chemotherapy for metastatic breast cancer: Results from CALGB 40502 (Alliance). Cancer Research. 78(4_Supplement). P1–7. 1 indexed citations

Burstein, HJ, Angela DeMichele, James Harnett, et al.. (2018). Abstract P3-11-01: Treatment patterns for young women with HR+/HER2- metastatic breast cancer in the United States in the era of CDK 4/6 inhibitors. Cancer Research. 78(4_Supplement). P3–11. 1 indexed citations

DeMichele, A., KD Miller, HS Rugo, et al.. (2018). Abstract PD5-06: Adjuvant palbociclib plus endocrine therapy for hormone receptor positive/HER2 negative breast cancer: A phase II feasibility study. Cancer Research. 78(4_Supplement). PD5–6. 1 indexed citations

Tolaney, SM, DA Yardley, Beverly Moy, et al.. (2013). Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Cancer Research. 73(24_Supplement). S1–4. 22 indexed citations

Vaz-Luís, Inês, et al.. (2013). Abstract P6-11-09: Impact of tumor subtype on clinical features, treatment, and clinical outcomes among breast cancer patients with central nervous system disease. Cancer Research. 73(24_Supplement). P6–11. 1 indexed citations

Olson, Erin M., Nancy U. Lin, Pamela J. DiPiro, et al.. (2011). Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Annals of Oncology. 23(1). 93–97. 22 indexed citations

Ligibel, JA, HJ Burstein, KD Miller, et al.. (2011). OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer.. Cancer Research. 71(24_Supplement). OT3–2. 3 indexed citations

Burstein, HJ, Lyndsay Harris, Karen S. Anderson, et al.. (2011). Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer.. Journal of Clinical Oncology. 29(15_suppl). e11074–e11074. 2 indexed citations

10.

Mayer, Erica L., JA Ligibel, HJ Burstein, et al.. (2010). TBCRC 012: ABCDE, a phase II randomized study of adjuvant bevacizumab, metronomic chemotherapy (CM), diet and exercise after preoperative chemotherapy for breast cancer.. Journal of Clinical Oncology. 28(15_suppl). TPS103–TPS103. 4 indexed citations

11.

Shak, S., H. S. Rugo, LA Carey, et al.. (2010). Abstract P3-10-13: Prognostic Value of Genomic Analysis after Neoadjuvant Chemotherapy for Breast Cancer. Cancer Research. 70(24_Supplement). P3–10. 1 indexed citations

12.

Mayer, Erica L., Anju Nohria, KD Miller, et al.. (2010). Cardiovascular safety of adjuvant bevacizumab for breast cancer.. Journal of Clinical Oncology. 28(15_suppl). 571–571. 5 indexed citations

13.

Isakoff, SJ, Jennifer Savoie, Joan D. Beckman, et al.. (2009). A phase I study of vandetanib and metronomic chemotherapy in advanced breast cancer.. Cancer Research. 69(2_Supplement). 906–906. 1 indexed citations

14.

Mayer, Erica L., Mark Kozloff, Barbara Klencke, et al.. (2009). SABRE-B: a randomized phase II trial evaluating the safety and efficacy of combining sunitinib (S) with paclitaxel (P) + bevacizumab (B) as first-line treatment for HER2-negative metastatic breast cancer (MBC): final results.. Cancer Research. 69(2_Supplement). 3126–3126. 7 indexed citations

15.

Burstein, HJ, et al.. (2009). Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer.. Cancer Research. 69(2_Supplement). 37–37. 37 indexed citations

16.

Burstein, HJ, Erica L. Mayer, Jeffrey Peppercorn, et al.. (2007). Dose-dense nab-paclitaxel (nanoparticle albumin-bound paclitaxel) in adjuvant chemotherapy for breast cancer: A feasibility study. Journal of Clinical Oncology. 25(18_suppl). 594–594. 5 indexed citations

17.

Burstein, HJ, Aparna Keshaviah, Ronald D. Hart, et al.. (2006). Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study. Journal of Clinical Oncology. 24(18_suppl). 650–650. 9 indexed citations

18.

Miller, Kathy D., HJ Burstein, Anthony Elias, et al.. (2005). Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). Journal of Clinical Oncology. 23(16_suppl). 563–563. 57 indexed citations

19.

Burstein, HJ, Lyndsay N. Harris, Carolyn M. Kaelin, et al.. (2001). Preoperative trastuzumab (T) and paclitaxel (P) for HER2-overexpressing (HER2+) stage breast cancer. European Journal of Cancer. 37. S146–S146. 5 indexed citations

20.

Bowie, Lemuel J., et al.. (1986). Degree of unsaturation of the fatty acid chains of phospholipids influences the fluorescence polarization: implications for evaluating fetal lung maturity.. Clinical Chemistry. 32(3). 425–428. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact